Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
You could win a cash prize of up to £25,000 when you play the Breakthrough T1D lottery. As well as the chance to win great prizes, you’ll also help fund our research to find a cure for type 1 diabetes.
Researchers need your help. By taking part in research studies and clinical trials, you will help them make progress to improve lives and find a cure for type 1 diabetes.
Our ambitious new roadmap is aimed at driving significant advancements in type 1 diabetes research, treatment, and care.
Your donation helps support people living with type 1 diabetes and funds the best treatment and cure research.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
Home > News & events > News > CGMs available on prescription from August 2022
Anyone with type 1 diabetes can now access real-time continuous glucose monitoring (CGM) through their GP or local hospital. Once prescribed, repeat prescriptions can be collected from local pharmacies.
The Dexcom ONE Real Time-Continuous Glucose Monitoring can now be prescribed on the NHS, across all four nations of the UK. This will help put into action the recently updated NICE guidelines in England and Wales on blood glucose monitoring, which say that anyone with type 1 should be offered CGM or flash glucose monitoring as part of standard care.
Patients will be provided with a sensor, transmitter and information on how to use it. The Dexcom ONE has much of the same functions as the G6 device, except for sharing and looping capabilities. Read the differences between the Dexcom devices.
CGMs use a sensor attached to the body which transmits real-time information on glucose levels to a handset or the user’s mobile phone, allowing them to check their glucose levels more often and without the need for painful finger prick tests.
CGMs also alert the user when glucose levels become too low or too high, meaning they are better able to avoid dangerous hypoglycaemia (hypos) or hyperglycaemia (hypers) which can potentially cause long-term complications. They also allow the user to review their glucose trends over time, rather than just giving a snapshot of when the test is taken, as is the case with finger prick tests.
We’ve been working with partners like Dexcom and organisations like NICE and NHS England to help bring about this sort of change for people with type 1.
Our Senior Technology Access Specialist, Lesley Jordan, says: “This is a major breakthrough in the treatment of type 1 diabetes which should allow everyone with type 1 access to this life changing technology. JDRF will work with local decision makers and people with type 1 diabetes to ensure equitable access to glucose monitoring technology as recommended by NICE.”
Whilst this device is now available to be prescribed on the NHS, it may take some time to be rolled out in all areas across the UK. People with type 1 should ask their clinician at their next appointment if it is available in their area, and if not, when it will be.
Researchers from John Hopkins University, USA, partially funded by Breakthrough T1D, have developed an experimental treatment that protects the insulin-producing cells from inflammatory damage, allowing them to survive for longer in animal models.
We are delighted with the decision to approve teplizumab for use on the NHS.
We look at a new feature coming to the CamAPS FX app, which will allow users to remove the need to count carbohydrates before a meal.
New data presented this week at the American Diabetes Association’s (ADA) 86th Scientific Sessions shows incredible promise: all 12 participants in the Eledon trial, testing the immunosuppressive drug tegoprubart, are no longer injecting insulin.
Don’t miss out on the latest research, inspiring stories, tech news, upcoming events, and handy information on living well with type 1. Join us now and receive it all straight to your inbox.
It’s thanks to your dedication that we have funded great progress in type 1 cure, treatment and prevention research. Help us to continue our vital research.
Would you like to visit the website of our {{ affiliate_country }} affiliate to complete your action?
